LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

LLY

1,159.67

+1.84%↑

JNJ

238

-0.36%↓

ABBV

224.7

-0.26%↓

UNH

405.21

-0.45%↓

MRK

120.56

+1.31%↑

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

17.64 -0.28

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.42

Massimo

18.03

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+115.47% upside

Dividendi
By Acuity
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-349M 1.5B
Apertura precedente	17.92
Chiusura precedente	17.64

Notizie sul Sentiment di mercato

By Acuity

34%

66%

87 / 344 Classifica in Healthcare

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 giu 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 giu 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 giu 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 giu 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 giu 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 giu 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 giu 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 giu 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 giu 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 giu 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 giu 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 giu 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 giu 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 giu 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 giu 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 giu 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 giu 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 giu 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 giu 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 giu 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 giu 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 giu 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 giu 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 giu 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 giu 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

115.47% in crescita

Previsioni per 12 mesi

Media 37.88 USD 115.47%

Alto 46 USD

Basso 29 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

87 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.